Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Sakari Vanharanta Clear advanced filters
  • The lineage transcription factor PAX8 is shown to play a pivotal part in determining cancer risk in clear cell renal cell carcinoma, providing insights into how genetic mutations lead to specific types of cancer.

    • Saroor A. Patel
    • Shoko Hirosue
    • Sakari Vanharanta
    ResearchOpen Access
    Nature
    Volume: 606, P: 999-1006
  • Primary and metastatic tumours have different metabolic phenotypes due to changes in nutrient availability. Here the authors perform multi-omic analyses of primary and metastatic renal cancer cells grown in a physiological medium and show that the reprogramming of the branched-chain amino acid catabolism and urea cycle through re-expression of ASS1 allows metabolic flexibility during renal cancer progression.

    • Marco Sciacovelli
    • Aurelien Dugourd
    • Christian Frezza
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-20
  • Lauri Aaltonen and colleagues show that a region on 8q24 associated with colorectal cancer risk functions as an enhancer and that the risk allele at this locus binds with higher affinity to the Wnt-regulated transcription factor TCF4 (also called TCF7L2), conferring enhanced responsiveness to Wnt signaling.

    • Sari Tuupanen
    • Mikko Turunen
    • Lauri A Aaltonen
    Research
    Nature Genetics
    Volume: 41, P: 885-890
  • Tenascin C is an extracellular matrix protein previously linked to breast cancer metastasis. Here the authors uncover how tenascin C promotes the fitness of metastasis-initiating cells by sustaining the stem and survival signaling pathways NOTCH and Wnt through specific regulation of Msi1 and Lgr5, respectively.

    • Thordur Oskarsson
    • Swarnali Acharyya
    • Joan Massagué
    Research
    Nature Medicine
    Volume: 17, P: 867-874
  • Whether the molecular drivers of tumor initiation are the same factors that promote metastasis during tumor progression is addressed in this report. In renal carcinoma, common primary driving alterations such as VHL loss do not necessarily correlate with outcome, and the authors show that additional epigenetic adaptations are required to unleash prometastatic behavior. Two important metastastic drivers, CXCR4 and CYTIP, are activated downstream of VHL loss through epigenetic reprogramming involving differential chromatin modification or DNA methylation, exemplifying the complex evolution of tumorigenic traits downstream of driving alterations.

    • Sakari Vanharanta
    • Weiping Shu
    • Joan Massagué
    Research
    Nature Medicine
    Volume: 19, P: 50-56
  • Tumour cells respond to an effective, targeted drug treatment with BRAF, ALK or EGFR kinase inhibitors by inducing a complex network of secreted signals that promote tumour growth, dissemination and metastasis of drug-resistant cancer cell clones, and increase the survival of drug-sensitive tumour cells, potentially contributing to incomplete tumour regression.

    • Anna C. Obenauf
    • Yilong Zou
    • Joan Massagué
    Research
    Nature
    Volume: 520, P: 368-372
    • Saroor A. Patel
    • Paulo Rodrigues
    • Sakari Vanharanta
    ReviewsOpen Access
    British Journal of Cancer
    Volume: 124, P: 3-12